• Long-term Efficacy of Octreotide in Patients with Polycystic Kidney and Liver Disease

Long-term Efficacy of Octreotide in Patients with Polycystic Kidney and Liver Disease

Three years of long-acting release octreotide (octreotide LAR) significantly reduced liver volume in patients with polycystic kidney and liver disease, researchers found in a placebo-controlled study. These reductions, reported in the July issue of Clinical Gastroenterology and Hepatology, were maintained for 2 years after treatment ended. Polycystic liver disease (PLD)

Read more